● **PATIENT AND CARER ADVICE**

Driving and skilled tasks Manufacturer advises patients and their carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness and fatigue.

● **NATIONAL FUNDING/ACCESS DECISIONS**

NICE decisions

▸ **Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (November 2019)** NICE TA611

Rucaparib (*Rubraca*®) is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement are followed.

Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop.

www.nice.org.uk/guidance/ta611

Scottish Medicines Consortium (SMC) decisions

SMC No. SMC2224

The *Scottish Medicines Consortium* has advised (March 2020) that rucaparib (*Rubraca*®) is accepted for restricted use within NHS Scotland as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. It is restricted to those patients who do not have a BRCA mutation. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

▸ **Rubraca** (Clovis Oncology UK Ltd) ▼

Rucaparib (as Rucaparib camsilate) 200 mg Rubraca 200mg tablets | 60 tablet PoM

Rucaparib (as Rucaparib camsilate) 250 mg Rubraca 250mg tablets | 60 tablet PoM

Rucaparib (as Rucaparib camsilate) 300 mg Rubraca 300mg tablets | 60 tablet PoM

Talazoparib

23-Oct-2019

● **DRUG ACTION** Talazoparib is a PARP inhibitor. PARP are enzymes that repair damaged DNA in cancer cells and, in the absence of functional BRCA, inhibition of PARP results in an inability of cancer cells to repair. Therefore inhibition of PARP results in an antineoplastic effect.

● **INDICATIONS AND DOSE**

Breast cancer (initiated by a specialist)

▸ BY MOUTH

▸ Adult: 1 mg once daily, for dose adjustments due to side-effects—consult product literature

DOSE ADJUSTMENTS DUE TO INTERACTIONS

▸ Manufacturer advises if concomitant use with P-glycoprotein inhibitors is unavoidable, reduce dose to 750 micrograms once daily.

IMPORTANT SAFETY INFORMATION

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES

See Cytotoxic drugs p. 938.

● **INTERACTIONS** → Appendix 1: talazoparib

● **SIDE-EFFECTS**

▸ **Common or very common** Alopecia · anaemia · appetite decreased · asthenia · decreased leucocytes · diarrhoea · dizziness · gastrointestinal discomfort · headache · nausea · neutropenia · stomatitis · taste altered · thrombocytopenia · vomiting

▸ **Frequency not known** Bone marrow depression · neoplasms

● **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception in women of childbearing potential during treatment and for 7 months after receiving the last dose. Male patients should use effective contraception during and for at least 4 months after treatment if their partner is pregnant or of childbearing potential. See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 938.

● **PREGNANCY** Manufacturer advises avoid—toxicity in *animal* studies. See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 938.

● **BREAST FEEDING** Manufacturer advises avoid during treatment and for 1 month after last dose—no information available.

● **HEPATIC IMPAIRMENT** Manufacturer advises avoid in moderate or severe impairment unless benefit outweighs risk (no information available).

● **RENAL IMPAIRMENT** Manufacturer advises avoid if creatinine clearance less than 30 mL/minute unless benefit outweighs risk (no information available).

Dose adjustments Manufacturer advises reduce starting dose to 750 micrograms once daily if creatinine clearance 30–60 mL/minute.

● **MONITORING REQUIREMENTS** Manufacturer advises monitor full blood count before treatment initiation, then monthly thereafter and as clinically indicated.

● **PATIENT AND CARER ADVICE**

Driving and skilled tasks Manufacturer advises patients and their carers should be counselled on the effects on driving and skilled tasks—increased risk of fatigue and dizziness.

● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 25

▸ **Talzenna** (Pfizer Ltd) ▼

Talazoparib (as Talazoparib tosylate) 250 microgram Talzenna 0.25mg capsules | 30 capsule PoM £1,655.00 (Hospital only)

Talazoparib (as Talazoparib tosylate) 1 mg Talzenna 1mg capsules | 30 capsule PoM £4,965.00 (Hospital only)

Venetoclax

07-Sep-2017

● **DRUG ACTION** Venetoclax is a potent, selective inhibitor of B-cell lymphoma-2 (BCL-2).

● **INDICATIONS AND DOSE**

Chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation when a B-cell receptor pathway inhibitor is unsuitable or ineffective (specialist use only) | Chronic lymphocytic leukaemia in the absence of 17p deletion or TP53 mutation when both chemo-immunotherapy and a B-cell receptor pathway inhibitor has been ineffective (specialist use only)

▸ BY MOUTH

▸ Adult: (consult product literature)

continued →